← All trials
NCT05351164
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2022
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Apr 28, 2022
- Last posted
- Apr 28, 2022
- Enrollment
- 2
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MichiganLead sponsor
- Amryt Research LimitedCollaborator
- University of MichiganOverall official - principal investigator
- University of MichiganReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.